Terms: = Breast cancer AND MYD88, Q99836, MYD88D, 4615
75 results:
1. Primary breast diffuse large B-cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group.
Weng H; Shrestha PR; Hong H; Chen Z; Yu L; Yao Y; Zhang Z; Zou L; Zhu B; Zhou H; Liu X; Liu Y; Guo H; Huang H; Lin T
Cancer Med; 2023 Dec; 12(23):21188-21198. PubMed ID: 37997571
[TBL] [Abstract] [Full Text] [Related]
2. Copy number variants landscape of multiple cancers and clinical applications based on NGS gene panel.
Yan K; Niu L; Wu B; He C; Deng L; Chen C; Lan Z; Lin C; Kuang W; Lin H; Zou J; Zhang W; Luo Z
Ann Med; 2023; 55(2):2280708. PubMed ID: 37967237
[TBL] [Abstract] [Full Text] [Related]
3. Differences in mutational signature of diffuse large B-cell lymphomas according to the primary organ.
Koh HH; Yoon SE; Kim SJ; Kim WS; Cho J
Cancer Med; 2023 Oct; 12(19):19732-19743. PubMed ID: 37706649
[TBL] [Abstract] [Full Text] [Related]
4. Looking for biomarkers in interferon response pathway to predict response to oncolytic HSV-1 in breast cancer: An ex vivo study.
Nejatipour Z; Teimoori-Toolabi L; Forooshani RS; Barough MS; Farahmand M; Biglari A; Azadmanesh K
Cancer Biomark; 2023; 38(1):37-47. PubMed ID: 37522197
[TBL] [Abstract] [Full Text] [Related]
5. Baicalein prevents capecitabine-induced heart damage in female Wistar rats and enhances its anticancer potential in MCF-7 breast cancer cells.
Ibrahim HA; Abd El-Alim AEF; El-Hafeez MA; Metwally MMM; Khamis T; Galal AAA
Life Sci; 2023 Apr; 319():121523. PubMed ID: 36842762
[TBL] [Abstract] [Full Text] [Related]
6. Genetic and Epigenetic Regulation of the Innate Immune Response to Gout.
de Lima JD; de Paula AGP; Yuasa BS; de Souza Smanioto CC; da Cruz Silva MC; Dos Santos PI; Prado KB; Winter Boldt AB; Braga TT
Immunol Invest; 2023 Apr; 52(3):364-397. PubMed ID: 36745138
[TBL] [Abstract] [Full Text] [Related]
7. Design of Novel IRAK4 Inhibitors Using Molecular Docking, Dynamics Simulation and 3D-QSAR Studies.
Bhujbal SP; He W; Hah JM
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234844
[TBL] [Abstract] [Full Text] [Related]
8. Intralesional TLR4 agonist treatment strengthens the organ defense against colonizing cancer cells in the brain.
Blazquez R; Chuang HN; Wenske B; Trigueros L; Wlochowitz D; Liguori R; Ferrazzi F; Regen T; Proescholdt MA; Rohde V; Riemenschneider MJ; Stadelmann C; Bleckmann A; Beißbarth T; van Rossum D; Hanisch UK; Pukrop T
Oncogene; 2022 Nov; 41(46):5008-5019. PubMed ID: 36224342
[TBL] [Abstract] [Full Text] [Related]
9. Curcumin ameliorates oxidized low-density lipoprotein (ox-LDL)-caused damage in human umbilical vein endothelial cells (HUVECs) through the miR-599/myd88/NF-κB axis.
Chen D; Zhu C; Ye S; Yang Q
Toxicol In Vitro; 2022 Dec; 85():105481. PubMed ID: 36156291
[TBL] [Abstract] [Full Text] [Related]
10. Tumor cell-released LC3-positive EVs promote lung metastasis of breast cancer through enhancing premetastatic niche formation.
Sun X; Wang X; Yan C; Zheng S; Gao R; Huang F; Wei Y; Wen Z; Chen Y; Zhou X; Liu X; Chen B; Shen Y; Cai Y; Pan N; Wang L
Cancer Sci; 2022 Oct; 113(10):3405-3416. PubMed ID: 35879596
[TBL] [Abstract] [Full Text] [Related]
11. Thymosin α-1 Reverses M2 Polarization of Tumor-Associated Macrophages during Efferocytosis.
Wei YT; Wang XR; Yan C; Huang F; Zhang Y; Liu X; Wen ZF; Sun XT; Zhang Y; Chen YQ; Gao R; Pan N; Wang LX
Cancer Res; 2022 May; 82(10):1991-2002. PubMed ID: 35364609
[TBL] [Abstract] [Full Text] [Related]
12. Advanced glycation end products correlate with breast cancer metastasis by activating RAGE/TLR4 signaling.
Pan S; Guan Y; Ma Y; Cui Q; Tang Z; Li J; Zu C; Zhang Y; Zhu L; Jiang J; Liu Z
BMJ Open Diabetes Res Care; 2022 Mar; 10(2):. PubMed ID: 35346972
[TBL] [Abstract] [Full Text] [Related]
13. Serum amyloid A 1 induces suppressive neutrophils through the Toll-like receptor 2-mediated signaling pathway to promote progression of breast cancer.
Niu X; Yin L; Yang X; Yang Y; Gu Y; Sun Y; Yang M; Wang Y; Zhang Q; Ji H
Cancer Sci; 2022 Apr; 113(4):1140-1153. PubMed ID: 35102665
[TBL] [Abstract] [Full Text] [Related]
14. The cytotoxicity and apoptotic effects of verbascoside on breast cancer 4T1 cell line.
Daneshforouz A; Nazemi S; Gholami O; Kafami M; Amin B
BMC Pharmacol Toxicol; 2021 Nov; 22(1):72. PubMed ID: 34844644
[TBL] [Abstract] [Full Text] [Related]
15. Synthesis of small molecules targeting paclitaxel-induced myd88 expression in triple-negative breast cancer cell lines.
Poh Yen K; Stanslas J; Zhang T; Li H; Wang X; Kok Meng C; Kok Wai L
Bioorg Med Chem; 2021 Nov; 49():116442. PubMed ID: 34600241
[TBL] [Abstract] [Full Text] [Related]
16. New developments in non-Hodgkin lymphoid malignancies.
Ganapathi KA; Brown LE; Prakash S; Bhargava P
Pathology; 2021 Apr; 53(3):349-366. PubMed ID: 33685720
[TBL] [Abstract] [Full Text] [Related]
17. NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative breast cancer Cells.
Quagliariello V; De Laurentiis M; Cocco S; Rea G; Bonelli A; Caronna A; Lombari MC; Conforti G; Berretta M; Botti G; Maurea N
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096896
[TBL] [Abstract] [Full Text] [Related]
18. The myd88 inhibitor TJ-M2010-2 suppresses proliferation, migration and invasion of breast cancer cells by regulating myd88/GSK-3β and myd88/NF-κB signalling pathways.
Liu JH; Chen C; Li ZY; Zou ZM; Gao DC; Zhang X; Kuang XW; Sun ZH; Zheng WJ; Zhou P; Sun SR
Exp Cell Res; 2020 Sep; 394(2):112157. PubMed ID: 32610185
[TBL] [Abstract] [Full Text] [Related]
19. Adherence to treatment guidelines and survival in older women with early-stage breast cancer in Denmark 2008-2012.
Vogsen M; Bille C; Jylling AMB; Jensen MB; Ewertz M;
Acta Oncol; 2020 Jul; 59(7):741-747. PubMed ID: 32364416
[No Abstract] [Full Text] [Related]
20. MicroRNA-4317 predicts the prognosis of breast cancer and inhibits tumor cell proliferation, migration, and invasion.
Sheng Y; Hu R; Zhang Y; Luo W
Clin Exp Med; 2020 Aug; 20(3):417-425. PubMed ID: 32279128
[TBL] [Abstract] [Full Text] [Related]
[Next]
